

Cocrystal Pharma to Present at the 12th Annual LD Micro Main Event

– Presentation on Tuesday, December 10th at 4:40 pm PST –

2019 (GLOBE NEWSWIRE) BOTHELL. WA. Dec. 04. -- Cocrystal Pharma, (NASDAQ: COCP), ("Cocrystal" or the "Company"), clinical а stage Inc. biotechnology company discovering and developing novel antiviral therapeutics, announced today that Dr. Gary Wilcox, Chairman and Chief Executive Officer of Cocrystal, will present a corporate overview at the 12th Annual LD Micro Main Event on Tuesday. December 10. 2019 at 4:40 pm PST in Bel-Air, CA.

In addition to the presentation, management will also be available to participate in one-onone meetings with qualified members of the investor community who are registered to attend the conference.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit <u>www.cocrystalpharma.com</u>.

Investor and Media Contact:

Jenene Thomas Communications, LLC (833) 475-8247 COCP@jtcir.com

###



Source: Cocrystal Pharma, Inc.